Skip to main content
SpringerLink
Log in

Malignes Pleuramesotheliom

Hoffnung durch CDK4/6-Hemmung mit Abemaciclib?

  • Journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Fennell DA et al. Lancet Oncol. 2022;23(3):374-81

  2. Scherpereel A et al. Lancet Oncol. 2019;20(2):239-53

  3. Fennell DA et al. Lancet Oncol. 2021;22(11):1533-40

  4. Baas P et al. Lancet. 2021;397(10272):375-86

  5. Tsai YC et al. Cancers (Basel). 2022;14(1):182

  6. Krug LM et al. Lancet Oncol. 2015;16(4):447-56

Download references

Author information

Authors and Affiliations

  1. FA für Onkologie, Lena-Christ-Str. 17, 82152, Planegg, Deutschland

    Andreas Schalhorn

Authors
  1. Andreas Schalhorn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schalhorn, A. Hoffnung durch CDK4/6-Hemmung mit Abemaciclib?. InFo Hämatol Onkol 25, 17–18 (2022). https://doi.org/10.1007/s15004-022-9034-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-022-9034-2

Search

Navigation